These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10660343)

  • 21. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
    Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL
    Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.
    Dai D; Tang J; Rose R; Hodgson E; Bienstock RJ; Mohrenweiser HW; Goldstein JA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):825-31. PubMed ID: 11714865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
    Keshava C; McCanlies EC; Weston A
    Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Wojnowski L; Hustert E; Klein K; Goldammer M; Haberl M; Kirchheiner J; Koch I; Klattig J; Zanger U; Brockmöller J
    J Natl Cancer Inst; 2002 Apr; 94(8):630-1; author reply 631-2. PubMed ID: 11959896
    [No Abstract]   [Full Text] [Related]  

  • 25. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.
    van Schaik RH; de Wildt SN; van Iperen NM; Uitterlinden AG; van den Anker JN; Lindemans J
    Clin Chem; 2000 Nov; 46(11):1834-6. PubMed ID: 11067821
    [No Abstract]   [Full Text] [Related]  

  • 26. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.
    Hustert E; Zibat A; Presecan-Siedel E; Eiselt R; Mueller R; Fuss C; Brehm I; Brinkmann U; Eichelbaum M; Wojnowski L; Burk O
    Drug Metab Dispos; 2001 Nov; 29(11):1454-9. PubMed ID: 11602521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.
    Powell IJ; Zhou J; Sun Y; Sakr WA; Patel NP; Heilbrun LK; Everson RB
    J Urol; 2004 Nov; 172(5 Pt 1):1848-52. PubMed ID: 15540736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
    Reichardt JK; Makridakis N; Henderson BE; Yu MC; Pike MC; Ross RK
    Cancer Res; 1995 Sep; 55(18):3973-5. PubMed ID: 7664265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
    Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
    Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
    London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
    Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel mutations of CYP3A4 in Chinese.
    Hsieh KP; Lin YY; Cheng CL; Lai ML; Lin MS; Siest JP; Huang JD
    Drug Metab Dispos; 2001 Mar; 29(3):268-73. PubMed ID: 11181494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
    Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese.
    Stephens EA; Taylor JA; Kaplan N; Yang CH; Hsieh LL; Lucier GW; Bell DA
    Pharmacogenetics; 1994 Aug; 4(4):185-92. PubMed ID: 7987402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations.
    Reyes-Hernández OD; Lares-Asseff I; Sosa-Macias M; Vega L; Albores A; Elizondo G
    Pharmacology; 2008; 81(2):97-103. PubMed ID: 17952011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity.
    García-Martín E; Martínez C; Pizarro RM; García-Gamito FJ; Gullsten H; Raunio H; Agúndez JA
    Clin Pharmacol Ther; 2002 Mar; 71(3):196-204. PubMed ID: 11907494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.
    Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M
    Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
    Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
    Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
    Spurdle AB; Goodwin B; Hodgson E; Hopper JL; Chen X; Purdie DM; McCredie MR; Giles GG; Chenevix-Trench G; Liddle C
    Pharmacogenetics; 2002 Jul; 12(5):355-66. PubMed ID: 12142725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hereditary prostate cancer and other genetic predispositions to prostate cancer.
    Cussenot O; Valeri A; Berthon P; Fournier G; Mangin P
    Urol Int; 1998; 60 Suppl 2():30-4; discussion 35. PubMed ID: 9607556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.